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Abstract
Background: According to the data provided by the Brazilian Ne-
phrology Society, between the years 2000 and 2011 the number of 
dialysis patients gradually increased. It is known aldosterone levels 
contribute to the onset of hypertension given the fact it is related 
to the increase in sodium absorption with a resultant increase of 
volemia. The aim of this study was to perform a systematic review 
regarding the relation between aldosterone levels and hemodialysis.
Methods: A review was performed, based on the articles provided 
by databases Lilacs and Medline, with the descriptors “aldosterone” 
AND “hemodialysis” until the year 2014. Those articles with the 
descriptors in their titles or abstracts, or that evaluated the relation 
between aldosterone and hemodialysis in trials with humans were 
included.
Findings: About 14 articles were excluded and 15 were included. 
Among the included articles, one was epidemiologic, five were cli-
nical trials, two were prospective cohorts and seven were reviews.
Conclusion: It was observed that aldosterone blockade in hemo-
dialysis patients represents an important and safe therapeutic strategy 
owing to the consequent proteinuria and blood pressure reduction. 
These factors help reduce cardiovascular risk. Moreover, this strategy 
contributes to decrease renal injury, suggesting a beneficial effect on 
the prevention of chronic kidney disease.
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Background
Dialysis is a treatment widely used by chronic kidney 
disease patients in Brazil. The data provided by the 
Brazilian Nephrology Society [1] indicate that bet-
ween the years 2003 and 2013 the number of pa-
tients under dialysis gradually increased, going from 
42,695 cases in 2000 to 100,397 in 2013, with more 
than half of these cases concentrated in the south 
and southeast of the country. In July of 2011, it can 
also be observed that 90.6% of these patients were 
undergoing hemodialysis and only 9.4% peritoneal 
dialysis [2].
It is also known that a great part of the patients 
who undergo dialysis not only suffer from chronic 
kidney disease but also from cardiovascular diseases. 
In an attempt to reduce the incidence of this kind 
of pathology, many of these patients start an anti-
hypertensive treatment that includes medications 
like angiotensin receptor blockers and angiotensin-
converting enzyme inhibitors.
Aldosterone, a type of mineralocorticoid which 
especially targets the kidneys, is secreted by the 
adrenal gland. It is produced from cholesterol when 
LDL molecules bind to coated pits on the adrenocor-
tical cell membranes and are internalized by endo-
cytosis, forming vesicles that, once in contact with 
lysosomes, form cholesterol vesicles.
Aldosterone function consists in the regulation 
of the electrolyte balance as it acts in the increase 
of natremia; in other words, it acts not only on re-
nal tubular cells, thus increasing the active sodium 
transport to the extracellular space, but also on the 
passive sodium reabsorption of the urinary filtra-
te. Simultaneously, it increases potassium secretion 
through renal tubular epithelial cells, especially in 
the principal cells of the renal tubules. In sum, aldos-
terone makes sodium be preserved in the extrace-
llular liquid as potassium is excreted in the urine [3].
Whenever aldosterone depletion occurs, potas-
sium ion concentration in the extracellular liquid 
may increase, and when this increase reaches 60 
to 100%, a high cardiac toxicity, with a decrease in 
contraction strength and arrhythmias, can be ob-
served.
Aldosterone plays an important pathophysiologi-
cal role given the fact it is related to the stimulation 
of cytokines, inflammatory cell recruitment and the 
participation in the production of growth factors. 
In addition, it not only modulates plasminogen ac-
tivator inhibitor but also is the key to the regulation 
of ion homeostasis. The mineralocorticoid receptors 
are present in epithelial and in many non-epithelial 
tissues, including the brain and the heart. Due to 
the paracrine/autocrine effects it exerts, aldosterone 
can induce endothelial dysfunction, reduce vascu-
lar compliance and cause vascular and myocardial 
fibrosis.
Potassium ion concentration and the renin-an-
giotensin system are the most important factors 
in aldosterone secretion regulation. This hormone, 
in turn, acts on the kidneys contributing to the 
excretion of potassium ion excess and increasing 
blood volume and, as a result, blood pressure [4]. 
Chronic Kidney Disease
Chronic kidney disease (CKD) refers to a persistent 
renal dysfunction in which the kidneys are perma-
nently prevented from playing their habitual roles. 
In such cases, a slow, progressive and irreversible 
depletion of a great number of functional nephrons 
occurs [5].
CKD, defined as the persistent reduction of 
creatinine clearance to levels lower than 60 ml/
min/1.73m2 during the period of 3 months and/or 
the alteration in the renal parenchymal architecture, 
is a known high risk factor for the development of 
cardiovascular diseases [6].
The main etiologies for CKD and terminal kidney 
diseases (TKD) are diabetes mellitus and hyperten-
sion. These factors, along with other elements of 
the metabolic syndrome, like obesity, contribute to 
the development and progression of renal injuries 
[6].
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Among the patients with CKD, a relation bet-
ween a progressive increase in cardiovascular disea-
ses as renal function decreases can be observed 
regardless of any pre-existing cardiovascular disea-
se. A population study performed by the National 
kidney Foundation [7] showed that the lower the 
glomerular filtration rate is, the higher the chances 
are of occurring cardiovascular events, a fact that 
confirms the relation mentioned above.
Aldosterone in Dialysis Patients
A treatment strategy that has been used with dialy-
sis patients nowadays includes the inhibition of al-
dosterone action or production. It impairs higher 
reabsorption of sodium and, as a consequence, 
contributes to a decrease in the blood volume with 
a resultant steadiness of blood pressure and the 
non- interference with the already compromised 
renal function. Moreover, since CKD is usually as-
sociated with a cardiopathy, the technique protects 
the often-injured cardiac muscle and helps prevent 
future injuries to it.
Recent studies show that aldosterone exerts 
many potentially important effects on cardiovas-
cular and renal diseases once it is also related to 
oxidative stress levels through the induction of 
NADPH-oxidase and the promotion of vascular in-
flammation. In addition, not only does it decrease 
the bioavailability of nitric oxide by altering the 
endothelial function, but it can also cause cardiac 
hypertrophy and fibrosis [8].
Today it is known that high levels of aldosterone 
in dialysis patients increase the risk of sudden car-
diovascular death; therefore, the control of these 
levels in such patients is of the utmost importance.
Aldosterone antagonists –spironolactone and 
eplerenone– act on the distal sodium-potassium 
exchange, which causes an important anti-hyper-
tensive effect, play a vital role in prolonging survival 
in patients under dialysis and prevent hypokalemia 
when associated with other thiazide diuretics. These 
drugs compete with aldosterone for their intracellu-
lar receptors thus inhibiting sodium retention and 
potassium secretion at a distal level [9].
The aim of the current study was to perform a 
systematic review on what has been published re-
garding aldosterone levels in hemodialysis patients.
Methods
A systematic review was performed in order to 
identify possible eligible studies from the databa-
ses Lilacs and Medline with the descriptors (MeSH) 
“aldosterone” AND “hemodialysis”. Those articles 
published in the English language until 2014 that 
used human subjects in the trials and had available 
abstracts were included.
Articles that related aldosterone to hemodialysis 
in their titles or abstracts were included.
The review was carried out by two independent 
researchers and evaluated by a third party investi-
gator when the work was done.
In both databases, articles with animal trials or 
case reports whose titles or abstracts did not con-
tain the selected descriptors or relevant information 
that complied with the aim of the study were ex-
cluded.
Results
Table 1 shows the relation between the selected 
articles and their objectives. Figure 1 shows the ar-
ticles inclusion and exclusion flowchart according to 
the criteria previously established.
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Table 1.  Articles selected and objectives.
Author 
(Year)
Year Study Desing Objective
Dreschler et 
al [10]
2013 Cohort To analyze the relationship between cortisol and aldosterone 
on the risk of sudden death from cardiac events in patients 
undergoing hemodialysis.
Matsumoto 
et al [11]
2014 Clinical Trial Analyze if spironolactone reduces the high incidence of 
mortality and morbidity on cardiovascular and cerebrovascular 
events in hemodialysis patients.
Flevari et al 
[12]
2013 Clinical Trial To investigate the effect of spironolactone in hemodialysis 
patients without heart failure.
Morishita et 
al [13]
2011 Clinical Trial To evaluate the efficacy of a direct renin inhibitor, aliskiren, on 
blood pressure and cardiovascular biomarkers for cardiovascular 
diseases.
Morishita et 
al [14]
2011 Review Discuss the effects of blockers of the renin-angiotensin-
aldosterone system in hemodialysis patients on the control of 
hypertension and prevention of cardiovascular diseases.
Nakano et al 
[15]
2010 Clinical Trial Comparatively analyze the use of efenodipina and amlodipine 
in patients on hemodialysis in relation to its effect on the renin-
angiotensin-aldosterone system.
Chua et al 
[16]
2012 Review Systematically review the evidence of the use of spironolactone 
in hemodialysis patients and the incidence of hyperkalemia.
Baker et al 
[17]
2012 Review Evaluate the support given by the literature on the use of 
mineralocorticoid antagonists in hemodialysis patients.
Matsumoto 
et al [18]
2009 Clinical Trial Evaluate the safe use of low doses of spironolactone in oliguric 
patients on hemodialysis.
Hung et al 
[19]
2013 Cohort Analyze the role of volume overload in the relationship between 
aldosterone and mortality in hemodialysis patients.
Bomback et 
al [20]
2009 Cross Sectional To show that the loss of renal function entails a change in the 
ratio of volume expansion with aldosterone levels.
Figure 1: Revision of literature flowchart.
"Aldosterone" ADN 
"Hemodialysis" 
Medline: 221 articles
Humans only 
- 36 articles
English 
- 34 articles
With abstract
- 34 articles
Selected: 9 articles. 
- 3 clinicla trials 
- 3 preospective cohort 
- 3 reviews
"Aldosterone" ADN 
"Hemodialysis" 
Lilacs: 457 articles
Humans only 
- 48 articles
English 
- 42 articles
With abstract
- 38 articles
Selected: 7 articles. 
- 1 cross sectional 
- 1 prospective cohort
- 5 clinicla trials
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Discussion
Cardiovascular Mortality Reduction
In a cohort study carried out by Dreschsler et al. 
[10], 1255 patients were followed up for 4 years. 
The aim was to evaluate if aldosterone and corti-
sol concentrations may affect cardiovascular mor-
tality and morbidity rates in patients with type 2 
diabetes undergoing hemodialysis. After this period 
the author observed that high levels of aldostero-
ne were directly related to cardiovascular sudden 
death. The risk of sudden death was 69% higher in 
the group of patients with aldosterone levels higher 
than 200pg/ mL when compared with the group of 
patients with levels lower than 15 pg/ mL. Therefo-
re, the study demonstrated that the high levels of 
aldosterone in these patients were directly related 
to the increase in the risk of cardiovascular sudden 
death. According to the authors, the use of aldos-
terone antagonist medications could be a strategy 
to help reduce this death rate.
According to Matsumoto et al. [11], spironolac-
tone, an aldosterone receptor inhibitor, slows athe-
rosclerosis progression with a resultant cerebro- and 
cardiovascular prevention, even when in small do-
ses, in hemodialysis patients. In his randomized stu-
dy, the author divided the patients into 2 groups: 
those who were medicated and those who were 
not. During the three-year follow-up the group that 
did not receive the medication had a higher rate of 
cardio- and cerebrovascular events (control group, 
with 12.5%) than the medicated group (with 5.7%). 
Therefore, the conclusion is that with the use of spi-
ronolactone the risk of cardio- and cerebrovascular 
deaths can be reduced, especially among hemo-
dialysis patients.
Flevari et al. [12] states that the use of spirono-
lactone in hemodialysis patients with cardiac in-
sufficiency has proved to be very effective when it 
comes to decreasing the risk of cardiovascular disea-
ses. However, data on the use of this medication in 
patients without cardiac insufficiency are still very 
scarce. In his study, fourteen hemodialysis patients 
without cardiac insufficiency received a placebo for 
four months and spironolactone for another four 
(25 mg three times a week after the dialysis session). 
At the end of the study, spironolactone induced 
beneficial effects not only in the duration and ex-
tension of reactive hyperemia but also in heart rate 
variability and blood pressure control. Thus, authors 
concluded that the use of this medication in these 
patients may be beneficial in cardiovascular outco-
mes. In other words, it may decrease cardiovascular 
mortality.
Renin-Angiotensin-Aldosterone System 
(RAAS) Blockade
In a clinical trial conducted by Morishita et al. [13], 
a total of 30 hypertensive hemodialysis patients re-
ceived aliskiren, a direct renin inhibitor, for 8 weeks. 
After the follow-up period, the medication reduced 
systolic and diastolic pressure in patients and in-
hibited markers of cardiovascular diseases, like na-
triuretic peptide and C-reactive protein. The result 
suggests that aliskiren was effective in the blood 
pressure control and that it must have a protective 
cardiovascular effect on hypertensive hemodialysis 
patients.
The RAAS inhibition in hypertensive hemodialy-
sis patients can prevent cardiovascular diseases [14]. 
Previous studies show that the use of RAAS inhibi-
tors may be effective in the blood pressure control 
to prevent cardiovascular disease in hemodialysis 
patients. Therefore, this review reinforces the idea 
that these medications exert beneficial effects on 
this group of patients.
A randomized study carried out by Nakano et 
al. [15] compared the effects of efonidipine and 
amlodipine, two calcium channel blockers, on the 
RAAS in hemodialysis patients. Twenty hypertensi-
ve hemodialysis patients randomly received 20-60 
mg of efonidipine twice a day and 2.5-7.5 mg of 
amlodipine once a day over a period of 12 weeks. 
Besides the measurement of blood pressure before 
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each dialysis session, routine hematological tests 
were performed and circulating RAAS system 
components were evaluated. At the end of the 
follow-up period, it was observed that systolic 
and diastolic pressure was significantly reduced 
by efonidipine. However, diastolic pressure did 
not reach statistical significance while amlodipi-
ne was being administered despite the fact plas-
ma renin activity and angiotensin II levels did 
not significantly vary during both periods. Results 
suggest that efonidipine not only blocks calcium 
channels but also suppresses aldosterone secretion 
by the adrenal glands. Thus, besides its anti-hy-
pertensive effect, efonidipine also provides cardio-
vascular protection against the harmful effects of 
aldosterone through a different mechanism than 
RAAS inhibitors.
Aldosterone Antagonism and 
Hyperkalemia
In order to analyze the medication safety in hemo-
dialysis patients, Chua et al. [16] conducted a review 
that evaluated the incidence of hyperkalemia in tho-
se patients that made use of spironolactone. The 
conclusion was that the use of spironolactone has 
been proved to be safe in patients with chronic kid-
ney disease undergoing short-term therapy under a 
strict control of electrolyte concentrations. Despite 
the results, the author believes that the use of the 
medication in the general population with cardiac 
insufficiency undergoing hemodialysis would be 
hasty and it should not be done indiscriminately at 
the present moment.
In a review published by Baker & White [17], ten 
articles were evaluated: nine on the use of spirono-
lactone and one on the use of eplerenone analyzing 
the impact on potassium levels in this population. 
The use of spironolactone and eplerenone, when in 
small doses, showed a slight increase in potassium 
concentration. The current literature shows that 
the use of mineralocorticoid receptor blockers can 
be safely used in hemodialysis patients, although 
further studies that include larger populations are 
required for this recommendation.
According to a clinical trial performed by Matsu-
moto et al. [18], the use of small doses of spirono-
lactone in oliguric patients on hemodialysis in the 
long run is clinically safe and it can reduce mortality 
rate among these patients. Nonetheless, the study 
also revealed that among these patients under stu-
dy, eleven of them had to interrupt the medication 
owing to the fact they presented with hyperkale-
mia. The rest of the studied population, a total of 
50 patients, showed higher potassium levels when 
compared with the levels in the beginning of the 
trial. Therefore, the use of this medication should 
be approached with caution.
Hypervolemia
In a cohort study carried out by Hung et al. [19], the 
outcome of 328 hemodialysis patients was evalua-
ted. Among these patients, a total of 36% showed 
evidence of fluid volume excess; namely, the relation 
between extracellular water and total volume was 
higher than 48% in these patients. Moreover, the 
group with high aldosterone levels had lower rates 
of mortality and cardiovascular events. Therefore, 
the study showed that in patients with hypervole-
mia, aldosterone no longer poses as a risk factor, 
but as a protection factor.
In another study by Bomback et al. [20], hemo-
dialysis patients showed an irregular relation bet-
ween blood volume and aldosterone concentration. 
In the study, the relation comparison was between 
hemodialysis patients and non-hemodialysis volun-
teers. The result was that the rates of aldosterone 
and extracellular volume were higher in hemodialy-
sis than in the evaluated volunteers. With these 
data, the conclusion is that both volume reduction 
and the use of mineralocorticoid blockers may be 
effective treatment approaches.
Arterial Pressure Control
In a study conducted by Shavit et al. [21], the 
hypothesis that aldosterone may cause hyperten-
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sion in a manner that does not involve renal so-
dium retention was tested. The author administered 
eplerenone twice a day over a period of 4 weeks. 
This aldosterone antagonist administration lowered 
the systolic pressure, but showed no effect on the 
diastolic pressure and aldosterone concentration. In 
sum, the medication reduced the systolic pressure 
without exerting effects on aldosterone plasma con-
centrations or on plasma renin activity. Potassium 
concentration slightly increased, a fact that leads 
us to the conclusion that the medication should be 
used with caution.
Carotid Intima-Media Thickness 
Regression
Among the effects presented by spironolactone, 
one is its capacity to inhibit the progression of the 
carotid intima-media thickness. In order to establish 
a dosage pattern regarding its safety and effecti-
veness, Vukusich et al. [22] randomly administered 
the medication and placebo to 50 hemodialysis pa-
tients. Administration was carried out three weeks 
later, after each dialysis session, over a period of 
two years. Periodic potassium concentration mea-
surements were performed, and at the end of the 
second year, subjects underwent a carotid ultra-
sound. A progression in carotid thickness values in 
the placebo group was seen whereas in the spiro-
nolactone group a regression could be observed. 
Thus, the medication showed a beneficial effect on 
the regression of intima-media thickness.
Cardiac Performance
Another spironolactone effect on hemodialysis pa-
tients is the probable improvement in the cardiac 
function. In a double-blind trial performed by Taheri 
et al. [23], a total of 16 hemodialysis patients were 
divide into 2 groups, and each received either pla-
cebo or spironolactone over a period of 6 months. 
Patients from the spironolactone group showed an 
increase in the ejection fraction when compared 
with the patients from the placebo group. Rates of 
hyperkalemia did not show any significant increase 
in either group. Therefore, as the use of spirono-
lactone implied an increase in the ejection fraction, 
it is observed that the medication can improve the 
cardiac performance.
In conclusion, there is a very close relation bet-
ween aldosterone values and chronic kidney disease 
patients undergoing hemodialysis. The current sys-
tematic review showed important interaction bet-
ween the renin-angiotensin-aldosterone system, hy-
pervolemia, cardiovascular mortality and alternative 
medications for aldosterone inhibition and a proper 
pressure control.
Conclusion
In conclusion, high levels of aldosterone in hemo-
dialysis patients were directly related to the increa-
se in the risk of cardiovascular sudden death and 
hypervolemia, and the use of aldosterone antago-
nist medications such as spironolactone could be a 
strategy to help reduce this death rate. Moreover, 
spironolactone is also associated to the progression 
of the carotid intima-media thickness inhibition 
and improvement in the cardiac function. However, 
the use of this medication should be approached 
with caution since it is related to some hyperkale-
mia events. Cardiovascular protection against the 
harmful effects of aldosterone is also provided by 
efonidipine, that besides blocking calcium channels 
also suppresses aldosterone secretion by the adrenal 
glands.
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